Merus N.V. announced on June 3, 2025, the launch of a proposed underwritten public offering of its common shares. All of the common shares in the offering are being sold by Merus.
The company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The offering is subject to market conditions and other closing conditions.
Merus intends to use the net proceeds from this offering, combined with its existing cash, cash equivalents, and marketable securities, to advance the clinical development of its product candidates, for preclinical research and technology development, and for general corporate purposes. This capital raise aims to support the company's ongoing growth initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.